Donahue Maria A, Brooks Julianne D, Hsu John, Price Mary, Blacker Deborah, Schwamm Lee H, Newhouse Joseph P, Westover M Brandon, Haneuse Sebastien, Moura Lidia M V R
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA.
Epilepsia. 2025 Apr 4. doi: 10.1111/epi.18396.
Acute ischemic stroke (AIS) is a leading hospitalization cause and significantly contributes to seizures among older adults. We examined outpatient epilepsy-specific medication (ESM) initiation patterns after AIS discharge in adults 65 years and older, trends over time (by stratifying the analysis from 2013 to 2021), and racial/ethnic differences.
We analyzed nationwide administrative claims data for a 20% sample of US Medicare beneficiaries (enrolled in Traditional Medicare Parts A, B, and D for at least 12 months before admission) aged ≥65 years and hospitalized for AIS between 2013 and 2021. We estimated the cumulative incidence of ESM initiation within 90 days after AIS discharge, with mortality as a competing risk and censoring person time if individuals experienced an inpatient readmission. We described drug type and stratified our analysis by race, ethnicity, US geographic region, hospital region, and year of discharge.
Of 128 174 community-dwelling beneficiaries after AIS discharge, 2435 (1.9%, 95% confidence interval [CI] = 1.8%-2.0%) initiated ESM within the 90-day follow-up period and levetiracetam was the most common medication across all years (81%). Mean age was 79 years (range = 65-110), 56% were female, 81% were non-Hispanic White, 10% were Black/African American, 5% were Hispanic, and 3% were Asian. The cumulative incidence of ESM initiation at 90 days in the overall sample was 1.4% (95% CI = 1.3%-1.4%); it was 1.8% (95% CI = 1.6%-2.1%) for Black/African American, 1.9% (95% CI = 1.6%-2.3%) for Hispanic, and 1.2% (95% CI = 1.2%-1.3%) for non-Hispanic White beneficiaries. The 90-day cumulative incidence also varied by US Census division, from 1.0% (95% CI = .8-1.3; West North Central) to 1.5% (95% CI = 1.3%-1.8%; East South Central). We observed an increase in ESM 90-day initiation over time, from 1.2% (95% CI = 1.0%-1.5%) in 2013 to 1.7% (95% CI = 1.5%-1.9%) in 2021. ESM initiation was 1.6% (95% CI = 1.4%-1.8%) in the 65-70-year age group and decreased in older age groups.
Black/African American and Hispanic beneficiaries had a higher 90-day incidence of post-AIS ESM initiation than non-Hispanic Whites. ESM initiation decreased in older age groups.
急性缺血性中风(AIS)是导致住院的主要原因,在老年人中显著增加了癫痫发作的风险。我们研究了65岁及以上成年人AIS出院后门诊癫痫特异性药物(ESM)的起始模式、随时间的趋势(通过对2013年至2021年的分析进行分层)以及种族/民族差异。
我们分析了全国范围内20%的美国医疗保险受益人的行政索赔数据,这些受益人年龄≥65岁,在2013年至2021年期间因AIS住院,且在入院前至少12个月参加了传统医疗保险A、B和D部分。我们估计了AIS出院后90天内ESM起始的累积发生率,将死亡率作为竞争风险,如果个体再次住院则对观察时间进行截尾。我们描述了药物类型,并按种族、民族、美国地理区域、医院区域和出院年份对分析进行分层。
在128174名AIS出院后的社区居住受益人中,2435人(1.9%,95%置信区间[CI]=1.8%-2.0%)在90天随访期内开始使用ESM,左乙拉西坦是历年最常用的药物(81%)。平均年龄为79岁(范围=65-110岁),56%为女性,81%为非西班牙裔白人,10%为黑人/非裔美国人,5%为西班牙裔,3%为亚洲人。总体样本中90天时ESM起始的累积发生率为1.4%(95%CI=1.3%-1.4%);黑人/非裔美国人为1.8%(95%CI=1.6%-2.1%),西班牙裔为1.9%(95%CI=1.6%-2.3%),非西班牙裔白人受益人为1.2%(95%CI=1.2%-1.3%)。90天累积发生率也因美国人口普查分区而异,从1.0%(95%CI=.8-1.3;西北中部)到1.5%(95%CI=1.3%-1.8%;东南中部)。我们观察到ESM 90天起始率随时间增加,从2013年的1.2%(95%CI=1.0%-1.5%)增至2021年的1.7%(95%CI=1.5%-1.9%)。65-70岁年龄组的ESM起始率为1.6%(95%CI=1.4%-1.8%),在老年组中有所下降。
黑人/非裔美国人和西班牙裔受益人在AIS后90天内ESM起始的发生率高于非西班牙裔白人。老年组的ESM起始率下降。